Saudi Journal of Kidney Diseases and Transplantation

ORIGINAL ARTICLE
Year
: 2008  |  Volume : 19  |  Issue : 2  |  Page : 206--209

Comparative Evaluation of Renal Findings in Beta-Thalassemia Major and Intermedia


Derakhshan Ali1, Karimi Mehran2, Abdolkarim Ghadimi Moghaddam3,  
1 Shiraz Nephro-Urology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 Hematology Oncology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Pediatrics, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence Address:
Derakhshan Ali
Associate Professor of Pediatrics and Pediatric Nephrology, Shiraz Nephro-Urology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz
Iran

Abstract

Thalassemia is a systematic disease in which the renal involvement has not yet been scrupulously studied. In a cross-sectional study, the renal findings of 50 cases of thalassemia intermedia (group 1) were compared to 58 patients with thalassemia major (group 2). Blood urea nitrogen, serum creatinine, uric acid, calcium, phosphorus, urinalysis, and ultrasonographical findings were evaluated. Mean age was 18 ± 3.0 in group 1 and 17 ± 3.5 years in group 2. The mean of serum ferritin levels was 871 ± 81.8 ng/ml in group 1 vs. 3503 ± 201 ng/ml in thalassemia major (p < 0.05). Ninety-two percent of the patients in group 1 were on hydroxyurea at the time of evaluation. Serum uric acid was significantly higher in group 1 than group 2 patients (5.74 ± 2.95 vs. 4.12 ± 0.9 mg/dl, p < 0.05). Microscopic hematuria (red blood cell in high power field of urine microscopy > 5) was observed among 19 children (17.6%); 17 of them were in group 1. In contrast, children with thalassemia major had significantly higher serum creatinine (0.89 ± 0.18 vs. 0.59 ± 0.37 mg/dl, p < 0.05) and blood urea nitrogen values (12.14 ± 5.58 vs. 13.85 ± 3.54 mg/dl, p < 0.05). We conclude that significant renal involvement is not a frequent complication in children and young adults suffering from thalassemia. Hyperuricemia and microscopic hematuria are more common in thalassemia intermedia than thalassemia major. Microscopic hematuria in thalassemia intermedia might be related to either hypercalciuria or hyperuricosuria.



How to cite this article:
Ali D, Mehran K, Moghaddam AG. Comparative Evaluation of Renal Findings in Beta-Thalassemia Major and Intermedia.Saudi J Kidney Dis Transpl 2008;19:206-209


How to cite this URL:
Ali D, Mehran K, Moghaddam AG. Comparative Evaluation of Renal Findings in Beta-Thalassemia Major and Intermedia. Saudi J Kidney Dis Transpl [serial online] 2008 [cited 2022 Jul 6 ];19:206-209
Available from: https://www.sjkdt.org/text.asp?2008/19/2/206/39031


Full Text

 Introduction



Thalassemia was first described by Dr. Cooley in 1925. [1] It is more prevalent in the Mediterranean Region, North and West Africa, the Middle East and some other parts of the world. [2] About 150 million people worldwide carry beta-thalassemia gene. High frequency of thalassemia gene is encountered in Sardinia (11-34%), Greece (5-15%), and Iran (4-10%). [3],[4],[5]

Thalassemia is the most common type of genetic abnormality in the world. According to our health ministry data, there are 20,000 registered thalassemia patients in Iran, of whom health care has a large burden on health budget and family economics.

Despite advances in chelating therapy, some major complications of thalassemia are inevitable. A large number of studies have been performed on different complications of thalassemia, however, there are a few studies on the renal involvement in this disease. [6],[7],[8]

We aim in this study to evaluate the renal manifestations in patients with thalassemia major and intermedia.

 Materials and Methods



We randomly selected 50 thalassemia inter­media children, who were under regular follow-up of a hematologist and did not receive regular transfusions (group 1), and compared their renal findings with 58 thalassemia major children who were on regular blood transfusion and chelation therapy (group 2). Thalassemia was diag­nosed in the study patients by complete blood count and hemoglobin electrophoresis. Children with diabetes and major cardiac complications were excluded from the study. The study protocol and laboratory evalua­tions were discussed with the patients and their parents and a written consent was obtained.

The medical records were reviewed meti­culously, and a complete physical exami­nation was performed. Repeated investigations included hemoglobin, urinalysis, serum calcium, phosphate, blood urea nitrogen (BUN), creatinine, serum ferritin, and abdo­minal ultrasonography. All the laboratory investigations were performed in the same reference laboratory, and all ultrasono­graphical evaluations were performed by the same expert ultrasonographist.

 Statistical analysis



Statistical analysis was performed by SPSS 11.5 software and T-test. P st blood transfusion or diagnosis was 3.24 ± 3.38 and 1.6 ± 1.31 years in group1 and 2, respectively. Children in thalassemia major group received more regular infusions of desferrioxamine than thalassemia intermedia group (72.5% vs. 10%, p > 5) was observed among 19 (17.6%) children, of whom 17 patients had thalassemia intermedia. Pyuria was also more common in group 1 than group 2 (12% vs. 5%, P: not significant). On the other hand, hemoglobinuria was observed in 10% of group 2 patients, but in none of the patients in group 1.

The mean renal size was slightly larger in group 1 than group 2, but was not statis­tically significant. A small renal stone of nonclinical importance was noticed in 2 children in group 1 and 1 child in group 2.

 Discussion



Blood transfusion is life saving for patients with thalassemia major, but loads body with excess iron that may result in hemosiderosis and its complications, inclu­ding multiple endocrinopathies, cardiomyo­pathy, and hepatic failure. Survival of patients has greatly improved following the intro­duction of desferrioxamine and regular iron chelation when serum ferritin level is maintained below 2,000 µg/L. [9] High serum ferritin level in thalassemia major group in this study was related to higher frequencies of blood transfusion and suboptimal use of desferrioxamine mostly due to poor compliance.

Although renal involvement could occur at tubular level in thalassemia major [6],[7],[8] and minor, [10] significant renal findings are not common. Renal failure is a terminal event in thalassemia major and is usually secondary to heart failure and/or hepatic failure. Acute renal failure following deferoxamine over­ dose or hemolysis has been reported. [11],[12],[13] There are numerous reports on complications of β-thalassemia in different organs, [14],[15],[16],[17],[18] but a few on renal complications. [6],[7],[8],[10] The results of this study compared the renal findings in children with thalassemia major and thalassemia intermedia. Children with thalassemia major had higher BUN and creatinine levels possibly due to higher iron deposition in their kidneys. Calcium and phosphate levels was lower in thalassemia major, which could be related either to liver or parathyroid involvement. However, the simultaneous low phosphorus level in our patients could not be explained by hypo­parathyroidism. We found significantly higher levels of uric acid in thalassemia intermedia group, which was predictable due to the higher cellular turnover secondary to the use of hydroxyurea. [19]

An important finding in our study was the significant number of children in thalassemia intermedia group who revealed microscopic hematuria. This finding might be related to either hyperuricosuria and hypercalciuria. However, further studies are required to confirm this speculation.

We conclude that significant renal involve­ment is not a frequent complication in children and young adults suffering from thalassemia. Hyperuricemia and microscopic hematuria are more common in thalassemia intermedia than thalassemia major. Micros­copic hematuria in thalassemia intermedia might be related to either.

 Acknowledgement



The authors wish to thank the vice chancellor for research for his financial support and also Dr. Hamed Jalaeian for his editorial assistance.

References

1Cooley TB, Lee P. Series of cases of splenomegaly in children with anemia and peculiar bone change. Trans Am Pediatr Soc 1925;37:29.
2Weatheall DJ, Clegg JB. The Thalassemia Syndrome, 3 rd ed. Boston, Blackwell Scientific Publication, 1981.
3Guiso L, Frogheri L, Pistidda P, et al. Frequency of delta+ 27-thalassaemia in Sardinians. Clin Lab Haematol 1996;18(4): 241-4.
4Lukens JN. The thalassemias and related disorders, quantitative disorders of hemoglobin synthesis. In: Lee GR, Bithell TC, Foerster J, et al, eds. Wintrobe's Clinical Hematology. 9th ed. Philadelphia: Lea & Febiger; 1993: 1102-45.
5Haghshenas M, Zamani J. [Thalassemia]. 1st ed. Shiraz: Shiraz University of Medical Sciences Publishing Center, 1997. [Book in Persian]
6Koliakos G, Papachristou F, Koussi A, et al. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol 2003;25(2):105-9.
7Michelakakis H, Dimitriou E, Georgakis H, et al. Iron overload and urinary lysosomal enzyme levels in beta-thalassaemia major. Eur J Pediatr 1997;156(8):602-4.
8Aldudak B, Karabay Bayazit A, Noyan A, et al. Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol 2000;15(1-2):109-12.
9Low LC. Growth, puberty and endocrine function in beta-thalassaemia major. J Pediatr Endocrinol Metab 1997;10(2):175-84.
10Cetin T, Oktenli C, Ozgurtas T, et al. Renal tubular dysfunction in beta-thalassemia minor. Am J Kidney Dis 2003;42(6):1164-8.
11Cianciulli P, Sorrentino F, Forte L, et al. Acute renal failure occurring during intra­venous desferrioxamine therapy: Recovery after haemodialysis. Haematologica 1992; 77(6):514-5.
12Prasannan L, Flynn JT, Levine JE. Acute renal failure following desferrioxamine overdose. Pediatr Nephrol 2003;18(3):283-5.
13Niwa T, Imoto M, Okubo M, Sassa H, Matsui E. Acute renal failure due to rhabdomyohaemolysis in beta-thalassaemic trait. Lancet 1979;2(8140):476-7.
14Low LC. Growth of children with [3­thalassemia major. Indian J Pediatr 2005; 72(2):159-64.
15Al-Rimawi HS, Jallad MF, Amarin ZO, Obeidat BR. Hypothalamic-pituitary-gonadal function in adolescent females with beta­thalassemia major. Int J Gynaecol Obstet 2005;90(1):44-7.
16Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev 2004;2(Suppl 2):285-91.
17Angelopoulos NG, Goula A, Rombopoulos G, Kaltzidou V, Katounda E, Kaltsas D,et al. Hypoparathyroidism in transfusion­dependent patients with beta-thalassemia. J Bone Miner Metab 2006;24(2):138-45.
18Grundy RG, Woods KA, Savage MO, Evans JP. Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. Arch Dis Child 1994;71(2):128-32.
19Samuels ML, Howe CD. Renal abnormalities induced by hydroxyurea. Cancer Chemother Rep 1964;40:9-13.